WELCOME TO PSIVIDA
Focused Therapeutics / Visionary Science
pSivida is a world leader in the development of tiny, sustained release, drug delivery products and technologies that are administered by implantation, insertion or injection.
Our proven proprietary technologies enable us to achieve highly focused long-term delivery of therapeutics. We have developed two of the three products approved by the FDA for the long-term sustained-release delivery of drug to treat chronic eye disease.
Our lead development product, Iluvien ®, utilizes Medidur™, our third generation miniaturized, sustained-release drug delivery technology to deliver fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), one of the leading causes of blindness in the developed world. On June 29, 2010 our licensee, Alimera Sciences filed a New Drug Application with the U.S. Food and Drug Administration for Iluvien for DME. Alimera requested priority review which, if granted, could result in an action letter from the FDA in the fourth quater of 2010. Alimera has also submitted a Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom as well as applications in multiple countries in the European Union.
pSivida, a NASDAQ listed company, is developing products designed to revolutionize treatments in critical areas such as ophthalmology, oncology and cardiology.
